310 related articles for article (PubMed ID: 32526980)
21. 17Beta-estradiol promotes aggressive laryngeal cancer through membrane-associated estrogen receptor-alpha 36.
Schwartz N; Chaudhri RA; Hadadi A; Schwartz Z; Boyan BD
Horm Cancer; 2014 Feb; 5(1):22-32. PubMed ID: 24081562
[TBL] [Abstract][Full Text] [Related]
22. Estrogens promote proliferation of the seminoma-like TCam-2 cell line through a GPER-dependent ERα36 induction.
Wallacides A; Chesnel A; Ajj H; Chillet M; Flament S; Dumond H
Mol Cell Endocrinol; 2012 Mar; 350(1):61-71. PubMed ID: 22138413
[TBL] [Abstract][Full Text] [Related]
23. Clinical Evidence on the Magnitude of Change in Growth Pathway Activity in Relation to Tamoxifen Resistance is Required.
Mansouri S; Farahmand L; Teymourzadeh A; Majidzadeh-A K
Curr Cancer Drug Targets; 2018; 18(7):668-676. PubMed ID: 28786348
[TBL] [Abstract][Full Text] [Related]
24. Role of ERα36 in membrane-associated signaling by estrogen.
Chaudhri RA; Schwartz N; Elbaradie K; Schwartz Z; Boyan BD
Steroids; 2014 Mar; 81():74-80. PubMed ID: 24252378
[TBL] [Abstract][Full Text] [Related]
25. Expression of ERα36 in gastric cancer samples and their matched normal tissues.
Wang J; Li J; Fang R; Xie S; Wang L; Xu C
Oncol Lett; 2012 Jan; 3(1):172-175. PubMed ID: 22740875
[TBL] [Abstract][Full Text] [Related]
26. Membrane estrogen signaling enhances tumorigenesis and metastatic potential of breast cancer cells via estrogen receptor-α36 (ERα36).
Chaudhri RA; Olivares-Navarrete R; Cuenca N; Hadadi A; Boyan BD; Schwartz Z
J Biol Chem; 2012 Mar; 287(10):7169-81. PubMed ID: 22247547
[TBL] [Abstract][Full Text] [Related]
27. Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer.
Schiff R; Osborne CK
Breast Cancer Res; 2005; 7(5):205-11. PubMed ID: 16168139
[TBL] [Abstract][Full Text] [Related]
28. Low concentrations of 17β-estradiol exacerbate tamoxifen resistance in breast cancer treatment through membrane estrogen receptor-mediated signaling pathways.
Xu Z; Zhao D; Zheng X; Huang B; Pan X; Xia X
Environ Toxicol; 2022 Mar; 37(3):514-526. PubMed ID: 34821461
[TBL] [Abstract][Full Text] [Related]
29. The elevated level of ERα36 is correlated with nodal metastasis and poor prognosis in lung adenocarcinoma.
Zhang S; Qiu C; Wang L; Liu Q; Du J
Steroids; 2014 Sep; 87():39-45. PubMed ID: 24928730
[TBL] [Abstract][Full Text] [Related]
30. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
31. The analysis of estrogen receptor-α positive breast cancer stem-like cells unveils a high expression of the serpin proteinase inhibitor PI-9: Possible regulatory mechanisms.
Lauricella M; Carlisi D; Giuliano M; Calvaruso G; Cernigliaro C; Vento R; D'Anneo A
Int J Oncol; 2016 Jul; 49(1):352-60. PubMed ID: 27121069
[TBL] [Abstract][Full Text] [Related]
32. ERα36, a variant of estrogen receptor α, is predominantly localized in mitochondria of human uterine smooth muscle and leiomyoma cells.
Yan Y; Yu L; Castro L; Dixon D
PLoS One; 2017; 12(10):e0186078. PubMed ID: 29020039
[TBL] [Abstract][Full Text] [Related]
33. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
[TBL] [Abstract][Full Text] [Related]
34. Concomitant high expression of ERα36, GRP78 and GRP94 is associated with aggressive papillary thyroid cancer behavior.
Dai YJ; Qiu YB; Jiang R; Xu M; Liao LY; Chen GG; Liu ZM
Cell Oncol (Dordr); 2018 Jun; 41(3):269-282. PubMed ID: 29368272
[TBL] [Abstract][Full Text] [Related]
35. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.
Li G; Zhang J; Jin K; He K; Zheng Y; Xu X; Wang H; Wang H; Li Z; Yu X; Teng X; Cao J; Teng L
Mol Oncol; 2013 Jun; 7(3):611-24. PubMed ID: 23499324
[TBL] [Abstract][Full Text] [Related]
36. Identification of ERbeta1 and ERbeta2 in human seminoma, in embryonal carcinoma and in their adjacent intratubular germ cell neoplasia.
Rago V; Romeo F; Giordano F; Ferraro A; Andò S; Carpino A
Reprod Biol Endocrinol; 2009 Jun; 7():56. PubMed ID: 19493328
[TBL] [Abstract][Full Text] [Related]
37. Effect of 17β-estradiol on estrogen receptor negative breast cancer cells in an osteolytic mouse model.
Cohen DJ; Patel V; Verma A; Boyan BD; Schwartz Z
Steroids; 2019 Feb; 142():28-33. PubMed ID: 29133279
[TBL] [Abstract][Full Text] [Related]
38. Expression of wild-type and variant estrogen receptor alpha in liver carcinogenesis and tumor progression.
Miceli V; Cocciadiferro L; Fregapane M; Zarcone M; Montalto G; Polito LM; Agostara B; Granata OM; Carruba G
OMICS; 2011 May; 15(5):313-7. PubMed ID: 21348637
[TBL] [Abstract][Full Text] [Related]
39. Estradiol induces bone osteolysis in triple-negative breast cancer via its membrane-associated receptor ERα36.
Cohen DJ; Dennis CD; Deng J; Boyan BD; Schwartz Z
JBMR Plus; 2024 May; 8(5):ziae041. PubMed ID: 38644978
[TBL] [Abstract][Full Text] [Related]
40. Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer.
Shah KN; Wilson EA; Malla R; Elford HL; Faridi JS
Mol Cancer Ther; 2015 Nov; 14(11):2411-21. PubMed ID: 26333382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
